The administration's focus on the Affordable Care Act, access to healthcare, and research may accelerate growth for these three stocks.
News & Analysis: Illumina
Sometimes the most carefully laid plans hit unforeseen snags.
The gene sequencing giant has a couple of key challenges going forward.
This giant of the genomic revolution ticks nearly all the boxes dividend investors should look for.
The chances are certainly higher now that the deal won't happen.
The biotech was under pressure last month, but it's bouncing back in April.
The DNA sequencing company is gearing up to report a big beat later this month.
The company's attempts to grow through acquisition keep running into problems.
Gene science will continue to drive the healthcare sector to new heights.
For long-term investors, the recent tech sell-off has discounted the following companies building the crucial technology platforms of tomorrow.